Company: BDRX
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001214659-25-005742
Chunk: 85

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-11
Form: 20-F
Item: Item 19
Chunk 85
---
-end cash and cash equivalent balances by currency:

  Schedule of foreign exchange risk                                   
 ──────────────────────────────────────────────────────────────────────
  Cash and cash equivalents:                                          
  Pounds Sterling                          212      2,244      2,588  
  US Dollar                              1,457      3,727        248  
  Euro                                       –          –          –  
  Total                                  1,669      5,971      2,836  

Foreign exchange risk also arises when
individual Group entities enter into transactions denominated in a currency other than their functional currency, the Group’s transactions
outside the UK to the US and Europe drive foreign exchange movements where suppliers invoice in currency other than sterling. The Group
does retain some cash balances in US Dollars from its US Dollar denominated equity raises to reduce the foreign exchange exposure on US$
denominated suppliers related to its NASDAQ listing and US based clinical trial. All other assets and/or consumables that are purchased
in foreign currencies, such currency is purchased immediately upon invoice. These transactions are not hedged because the cost of doing
so is disproportionate to the risk.

Foreign currency sensitivity
analysis

The most significant currencies in which
the Group transacts, other than Pounds Sterling, are the US Dollar and the Euro. The Group also trades in other currencies in small amounts
as necessary.

The following table details the Group’s
sensitivity to a 10% change in year-end exchange rates, which the Group feels is the maximum likely change in rate based upon recent currency
movements, in the key foreign currency exchange rates against Pounds Sterling:

  Schedule of foreign currency exchange rates                                                         
  Year ended 31 December 2024                      US Dollar               Euro       Other           
                                                                                                      
                                                   £’000                   £’000      £’000           
 ──────────────────────────────────────────────────────────────────────────────────────────────────────
  Loss before tax                                                 146                            ( 1  
  Total equity                                                    146                            ( 1  

  Year ended 31 December 2023      US Dollar               Euro               Other  
                                                                                     
                                   £’000                   £’000              £’000  
 ─────────────────────────────────────────────────────────────────────────────────────
  Loss before tax                                 373                  2             
  Total equity                                    373                  2             

  Year ended 31 December 2022      US Dollar              Euro                Other  
                                                                                     
                                   £’000                  £’000